Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Plerixafor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34 result(s) found for: Plerixafor. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-004122-41 Sponsor Protocol Number: 1 Start Date*: 2017-04-10
    Sponsor Name:Medical University Vienna, Dept. f. Transfusion Medicine
    Full Title: Plerixafor for stem cell mobilization in patients with multiple myeloma who mobilize moderate to optimize collection results - a randomized, placebo-controlled, double-blind study
    Medical condition: Stem cell mobilization with mozobil (plerixafor) in patients with multiple myeloma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004272-29 Sponsor Protocol Number: 14-MI-10 Start Date*: 2015-03-30
    Sponsor Name:Great Ormond Street Hospital NHS foundation Trust
    Full Title: Phase II clinical trial to evaluate safety and efficacy of mobilisation and collection of CD34+ cells after treatment with plerixafor and filgrastim in patients with Fanconi anaemia for subsequent ...
    Medical condition: Fanconi Anaemia
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000973-30 Sponsor Protocol Number: AMD-THAL Start Date*: 2011-04-28
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: PLERIXAFOR MOBILIZED STEM CELLS AS SOURCE FOR GENE THERAPY OF BETA-THALASSEMIA AMD-THAL .
    Medical condition: transfusion dependent beta thalassemia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10043391 Thalassaemia beta PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000117-31 Sponsor Protocol Number: CAM-PLEX Start Date*: 2015-03-03
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: To assess the safety of continuous IV administration of the CXCR4 antagonist, plerixafor (Mozobil), at potentially active plasma concentrations and assess its impact on the immune microenvironment ...
    Medical condition: Pancreatic adenocarcinoma High grade serous ovarian adenocarcinoma Colorectal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000659-10 Sponsor Protocol Number: LMW-DS-103 Start Date*: 2014-05-21
    Sponsor Name:TikoMed AB
    Full Title: A randomised, open-label, placebo-controlled, single centre study in healthy male volunteers to explore efficacy, safety and tolerability of single doses of low molecular weight dextran sulfate (LM...
    Medical condition: Healthy volunteers (mobilization of haematopoietic stem cells)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10053948 Hematopoietic stem cell mobilization LLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001245-13 Sponsor Protocol Number: 4LB-LEO-P Start Date*: 2022-03-03
    Sponsor Name:4Living Biotech SAS
    Full Title: A randomized, double-blind, placebo-controlled, two parallel groups, international multicenter trial to evaluate the effect of Plerixafor in acute respiratory failure related to COVID-19 (LEONARDO)
    Medical condition: Severe COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    23.1 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002356-27 Sponsor Protocol Number: XCGD_MOBI1 Start Date*: 2015-10-16
    Sponsor Name:Ospedale San Raffaele
    Full Title: A multicentric, exploratory, non-randomised, non-controlled, prospective, open-label phase II, study evaluating safety and efficacy of IBU, G-CSF and Plerixafor as a stem cell mobilization regimen ...
    Medical condition: X-linked chronic granulomatous disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10008906 Chronic granulomatous disease PT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019340-40 Sponsor Protocol Number: MOZ15609-DFI12860 Start Date*: 2010-08-23
    Sponsor Name:Genzyme Europe B.V.
    Full Title: A Phase 1/2 Combined Dose Ranging and Randomised, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cel...
    Medical condition: Paediatric cancer patients (aged 1 to <18 years) with Ewing’s sarcoma/soft tissue sarcoma, lymphoma, neuroblastoma and all other malignancies (excluding leukaemia) who are planned to undergo high d...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) ES (Completed) BE (Completed) HU (Completed) CZ (Completed) NL (Completed) DK (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023029-39 Sponsor Protocol Number: Plerixafor-MM02 Start Date*: 2012-02-21
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Plerixafor MM02 - Plerixafor plus G-CSF after chemotherapy for the mobilization of Peripheral Blood Stem Cells (PBSCs) in Multiple Myeloma (MM) patients undergoing Autologous Stem Cell Transplanta...
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004783-30 Sponsor Protocol Number: ARD12858-MOZ23510 Start Date*: 2013-01-21
    Sponsor Name:Sanofi aventis recherche et développement
    Full Title: A pilot, exploratory, randomized, phase 2 safety study evaluating tumor cell (plasma cell) mobilization and apheresis product contamination in plerixafor plus non-pegylated G-CSF mobilized patients...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) LT (Completed) SE (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006197-88 Sponsor Protocol Number: FANCOSTEM-1 Start Date*: 2012-03-22
    Sponsor Name:Cristina Díaz de Heredia Rubio
    Full Title: Clinical Phase II Trial to evaluate efficacy and safety of CD34+ cells mobilization and collection after treatment with plerixafor and filgrastim in patients with Fanconi anemia for subsequent tra...
    Medical condition: Fanconi anemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10055206 Fanconi's anemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-023436-16 Sponsor Protocol Number: HOVON 107 Start Date*: 2011-05-31
    Sponsor Name:HOVON Foundation
    Full Title: The feasibility and efficacy of subcutaneous and intravenous Plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: a randomized phase II study.
    Medical condition: stem cell mobilization
    Disease: Version SOC Term Classification Code Term Level
    12.1 10053948 Hematopoietic stem cell mobilization LLT
    12.1 10024329 Leukemia LLT
    12.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Restarted)
    Trial results: View results
    EudraCT Number: 2008-000689-21 Sponsor Protocol Number: MOZ008-08 Start Date*: 2008-07-21
    Sponsor Name:Genzyme Europe BV
    Full Title: Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple M...
    Medical condition: Mobilisation of peripheral blood stem cells prior to autologous stem cell transplantation in patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple Myeloma (MM).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029547 Non-Hodgkin's lymphoma LLT
    9.1 10020206 Hodgkin's disease LLT
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005320-16 Sponsor Protocol Number: AMD3100-3102-LTF Start Date*: 2007-09-25
    Sponsor Name:Genzyme Europe BV
    Full Title: Long-term Observational Follow-up Study of a Multicenter, Randomized, Double-blind, Placebo-controlled, Comparative Trial of AMD3100 (240 µg/kg) plus G-CSF (10 µg/kg) Versus G-CSF (10 µg/kg) plus P...
    Medical condition: Survival of multiple myeloma patients following autologous transplant in study AMD3100-3102.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024446-30 Sponsor Protocol Number: 00109 Start Date*: 2012-03-09
    Sponsor Name:AZIENDA OSPEDALIERA CARDINALE G.PANICO-TRICASE (LECCE)
    Full Title: A PHASE II STUDY OF CHEMOTHERAPY, MOZOBIL AND G-CSF AS MOBILIZING THERAPY FOR DOUBLE AUTOLOGOUS TRANSPLANTATION (ASCT) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL NON HODGKIN LYMPH...
    Medical condition: DIFFUSE LARGE B CELL NON HODGKIN LYMPHOMA (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013798-16 Sponsor Protocol Number: Start Date*: 2010-02-01
    Sponsor Name:Royal Liverpool and Broadgreen University Hospitals NHS Trust
    Full Title: A comparison of plerixafor/G-CSF with chemotherapy/G-CSF for stem cell transplantation
    Medical condition: Patients with lymphoma or myeloma, who require high dose chemotherapy with autologous stem cell rescue (known colloquially as an autograft). Plerixafor is used to mobilise the autologous stem cells...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10053946 Stem cell mobilization LLT
    14.0 10042613 - Surgical and medical procedures 10019028 Blood and blood product treatment HLT
    14.0 10042613 - Surgical and medical procedures 10042613 Surgical and medical procedures SOC
    14.0 10042613 - Surgical and medical procedures 10025309 Haematological and lymphoid tissue therapeutic procedures HLGT
    14.0 10042613 - Surgical and medical procedures 10053943 Haematopoietic stem cell mobilisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001741-14 Sponsor Protocol Number: TEM-MM-101 Start Date*: 2018-12-13
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: A phase I/II dose escalation study evaluating safety and activity of autologous CD34+-enriched hematopoietic progenitor cells genetically modified with a lentiviral vector encoding for the human in...
    Medical condition: Multiple myeloma in early relapse after intensive front line therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003489-41 Sponsor Protocol Number: CADPT03A12101 Start Date*: 2021-02-24
    Sponsor Name:NOVARTIS PHARMA AG
    Full Title: A first-in-patient Phase I/II clinical study to investigate the safety and efficacy of genome-edited hematopoietic stem and progenitor cells in subjects with severe complications of sickle cell dis...
    Medical condition: Sickle Cell Disease (SCD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021444-18 Sponsor Protocol Number: SPON845-10 Start Date*: 2010-10-18
    Sponsor Name:Cardiff University
    Full Title: TO ESTABLISH THE FEASIBILITY OF COMBINING EITHER THE TYROSINE KINASE INHIBITOR AC220 OR THE CXCR4 INHIBITOR PLERIXAFOR OR THE HSP90 INHIBITOR, GANETESPIB, WITH CHEMOTHERAPY IN OLDER PATIENTS WITH A...
    Medical condition: Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017346-32 Sponsor Protocol Number: 201228 Start Date*: 2010-03-15
    Sponsor Name:Fondazione Telethon
    Full Title: A PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME
    Medical condition: Wiskott-Aldrich Syndrom
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10061598 Immunodeficiency PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 08 07:14:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA